<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li X</submitter><funding>Genome Canada and Genome BC</funding><pagination>64</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12480863</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(1)</volume><pubmed_abstract>Gamma-butyrobetaine hydroxylase (BBOX1) catalyses the last step of carnitine biosynthesis, converting γ-butyrobetaine (γ-BB) into L-carnitine. Here we show, for the first time, that biallelic variants in BBOX1 are associated with decreased levels of L-carnitine and increased plasma levels of γ-BB in three patients from two unrelated families presenting with myopathic, neurodevelopmental, and late-onset psychiatric manifestations. Using a knockout C. elegans model of BBOX1 homolog, gbh-1, and strains harboring patient-derived variants (gbh-1(D72G) for p.Asp59Gly, gbh-1(G283R) for p.Gly263Arg, and gbh-1(G247Vfs6) for p.Gly227Valfs*6), we show very low L-carnitine levels and significantly elevated γ-BB in c.675delA and c.787G>A mutants, and moderately elevated γ-BB in c.176A>G. Furthermore, w</pubmed_abstract><journal>NPJ genomic medicine</journal><pubmed_title>Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine.</pubmed_title><pmcid>PMC12480863</pmcid><funding_grant_id>275SIL</funding_grant_id><pubmed_authors>Horvath G</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Rakic B</pubmed_authors><pubmed_authors>Mwenifumbo J</pubmed_authors><pubmed_authors>Stockler-Ipsiroglu S</pubmed_authors><pubmed_authors>Arbour L</pubmed_authors><pubmed_authors>Vaz FM</pubmed_authors><pubmed_authors>Lehman A</pubmed_authors><pubmed_authors>Tarailo-Graovac M</pubmed_authors><pubmed_authors>Jacob KJ</pubmed_authors><pubmed_authors>Yeganeh M</pubmed_authors><pubmed_authors>Sinclair G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine.</name><description>Gamma-butyrobetaine hydroxylase (BBOX1) catalyses the last step of carnitine biosynthesis, converting γ-butyrobetaine (γ-BB) into L-carnitine. Here we show, for the first time, that biallelic variants in BBOX1 are associated with decreased levels of L-carnitine and increased plasma levels of γ-BB in three patients from two unrelated families presenting with myopathic, neurodevelopmental, and late-onset psychiatric manifestations. Using a knockout C. elegans model of BBOX1 homolog, gbh-1, and strains harboring patient-derived variants (gbh-1(D72G) for p.Asp59Gly, gbh-1(G283R) for p.Gly263Arg, and gbh-1(G247Vfs6) for p.Gly227Valfs*6), we show very low L-carnitine levels and significantly elevated γ-BB in c.675delA and c.787G>A mutants, and moderately elevated γ-BB in c.176A>G. Furthermore, w</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-03T23:09:41.308Z</modification><creation>2026-05-02T03:12:03.574Z</creation></dates><accession>S-EPMC12480863</accession><cross_references><pubmed>41022783</pubmed><doi>10.1038/s41525-025-00523-2</doi></cross_references></HashMap>